Triple Negative Breast Cancer Vaccine Offers New Hope
Triple-negative breast cancer is an emerging cancer that has no effective treatment options, and it is very hard to treat, as there are no common receptors present to target. A new vaccine under phase 1 clinical trials has shown the best results in treating the cancer.Â
New Breast Cancer Vaccine Shows Promising Results: 74% of Patients Show Immune Response in Phase 1 Trial. At the San Antonio Breast Cancer Symposium, researchers introduced a vaccine that is under trial to treat triple-negative breast cancer. This creates a huge impact on the medical history. Most of the breast cancers have only a few treatment options. Mostly radiotherapy and chemotherapy were used as the only options to kill the cancer-causing cells.
Now this vaccine directly targets the immune system to trigger and response and fight against the cancer-causing cells. And after the trial, the results say that this vaccine is safe to use and with well-tolerated at different dosages.Â
How the vaccine works:
This vaccine is designed in such a way that it trains the immune system to recognize the cancer cells and attack them. Researchers were also involved to ensure the safety and efficacy of the vaccine dosages. They said that this vaccine is safe to use with a few side effects. The side effects include redness and irritation at the place where it is injected. No serious effects were noted.
Why this breakthrough matters:
We know that oncology plays an important role in healthcare systems, and cancer is the most common case seen in patients with limited treatment options and less explored. So, novel therapies and strategies are needed for the current situation.
And it is believed that the future trials show the effectiveness of the vaccine, then this will become the strategy that can be incorporated into the field of oncology for better patient outcomes. Even though the first phase of vaccine trials showed positive results, it is very important to take this phase to the second and third as well to test the efficacy better on individuals and for the long-term benefits.
The Road Ahead: Cleveland Clinic and Anixa Biosciences are planning further studies to test the vaccine’s efficacy among various patients. If these further trials become successful, then this will be a life-saving opportunity for the patients who are suffering from TNBC. This will be a major step towards fighting against one of the deadliest forms of cancer.
